Under varying physical forces exhibited in vivo, treatment of tumour cells with an EpCAM-targeted PLGA particle platform enhanced a subsequent injection of soluble TRAIL delivered via the circulation, and reduced both circulating tumour cells in blood and overall tumour cell burden by over 90%. The gene discussed is TNFSF10; the disease is neoplasm.